Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 3/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | LAP3 | P28838 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18039277 | 0.86 | MMP1 (0.45) | PGDMMP1MMP2MMP3MMP9 | |
| SCHEMBL5718402 | 0.86 | MMP1 (0.45) | PGDMMP1MMP2MMP3MMP9 | |
| SCHEMBL28281334 | 0.84 | MMP1 (0.43) | PGDMMP1MMP2MMP3MMP9 | |
| SCHEMBL18007399 | 0.83 | PGD (0.37) | PGDMMP1MMP2MMP3MMP9 | |
| SCHEMBL11400720 | 0.82 | MMP1 (0.52) | PGDMMP1MMP2MMP3MMP9 | |
| SCHEMBL2963336 | 0.77 | TSHR (0.41) | PGDMMP1MMP2MMP3MMP9 | |
| SCHEMBL4214657 | 0.77 | PDE4A (0.39) | PGDTSHRCYP2C9 | |
| SCHEMBL7528841 | 0.75 | TSHR (0.38) | PGDTSHRTP53RNPEPSLC7A5 | |
| Propylene Glycol SCHEMBL3729380 | 0.74 | TDP1 (0.39) | PGDMMP1MMP2MMP3MMP9 | |
| SCHEMBL14721767 | 0.74 | RARB (0.41) | PGDMMP1MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106349089-A | Method using tartrate-polybasic acid complex to extract and separate metoprolol enantiomer | 湖南理工学院 | 2017-01-25 | — | — | CN | claimed |
| CN-103922877-B | Double-aqueous phase system chiral separation Omprazole compound | 湖南如虹制药有限公司 | 2016-07-06 | — | — | CN | claimed |
| CN-103951653-B | The method of two-phase identification fractional extraction separation pantoprazole sodium enantiomers | 湖南理工学院 | 2016-06-29 | — | — | CN | claimed |
| CN-106349089-A | Method using tartrate-polybasic acid complex to extract and separate metoprolol enantiomer | 湖南理工学院 | 2017-01-25 | — | — | CN | disclosed |
| CN-103951653-B | The method of two-phase identification fractional extraction separation pantoprazole sodium enantiomers | 湖南理工学院 | 2016-06-29 | — | — | CN | disclosed |
| CN-103951653-B | The method of two-phase identification fractional extraction separation pantoprazole sodium enantiomers | 湖南理工学院 | 2016-06-29 | — | — | CN | disclosed |
| EP-1582209-B1 | THE USE OF SUCCINATE DERIVATIVE ESTERS FOR THE TREATMENT OF DEMENTIA | INST MATERIA MEDICA CAMS (CN) | 2012-09-19 | — | — | EP | disclosed |
| US-7557089-B2 | Use of derivatives of succinate esters for the treatment of dementia | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCE (CN) | 2009-07-07 | — | — | US | disclosed |
| US-20060281692-A1 | Use of derivatives of succinate esters for the treatment of dementia | BEIJING LIANXIN PHARMACEUTIC CO., LTD. (CN) | 2006-12-14 | — | — | US | disclosed |
| CN-1731991-A | Use of succinic acid derivative ester compounds for treating dementia | INST MATERIA MEDICA CAMS (CN) | 2006-02-08 | — | — | CN | disclosed |
| CN-1712057-A | Preparation of succinic acid carbobenzoxy derivative of orchid family plant effective part | DRUG INST CHINESE ACADEMY OF M (CN) | 2005-12-28 | — | — | CN | disclosed |
| EP-1582209-A1 | THE USE OF SUCCINATE DERIVATIVE ESTERS FOR THE TREATMENT OF DEMENTIA | THE INSTITUTE OF MATERIA MEDICA OF CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2005-10-05 | — | — | EP | disclosed |
| CN-1511520-A | Use of succinate derivative for biologically treating dementia | �й�ҽѧ��ѧԺҩ���о��� | 2004-07-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281692-A1 | Use of derivatives of succinate esters for the treatment of dementia | BCHE, ACHE, SI | PGD 118/4885MMP1 848/4885MMP2 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.